💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Chimerix, Inc. (CMRX)
« Back to company indexCMRX Chatter Timeline
Stock Ticker for CMRX
Most Active Tweeters for CMRX
| User | Tweets |
|---|---|
| @FlashAlert_me | 5 |
| @InsiderAlerts4U | 4 |
| @Tickeron | 4 |
| @semodough | 3 |
| @ChartMill | 3 |
Recent Tweets for CMRX
 |
@ChartMill $CMRX has a poor technical rating and the quality of the setup is also only medium at the moment.… https://t.co/9nzzt6adxu 1:01am |
 |
@ColoBigM @semodough $CMRX - Where are you finding that they exercised the new options? I only see Form 4's for the award of options. TIA... January 25th 2022, 8:01pm |
 |
@hesham_monica $CMRX Awaiting Buy Signal. Free Trial https://t.co/wUyihfppva https://t.co/WPMzFmMgtb January 25th 2022, 4:01pm |
 |
@Gambiste1 RT @leeryangames: @disclosetv IVE BEEN LONG $CMRX and $SIGA LETS GOOOOOOOOOO PAYDAY BABY January 25th 2022, 1:01pm |
 |
@leeryangames @disclosetv IVE BEEN LONG $CMRX and $SIGA LETS GOOOOOOOOOO PAYDAY BABY January 25th 2022, 1:01pm |
 |
@MarketChmln $CMRX option volume was 6X normal on Friday with 3,113 contracts. Call volume was 5% and put volume was 95%. https://t.co/ANS8LyRX58 January 23rd 2022, 10:01pm |
 |
@userFZ3 Some good companies to make profit off the fuckery are $SIGA and $CMRX. Though I wouldn’t buy them right now. Let t… https://t.co/pcJVSBGcZP January 23rd 2022, 2:01am |
 |
@SweepCastApp SweepCast alerted: $CMRX with Unusual Options Activity Alerted on $5 PUT Expiring: 02-18-2022 worth 137K? |? Learn… https://t.co/6N4wZrKlz1 January 23rd 2022, 12:01am |
|
@leeryangames @disclosetv $CMRX AND $SIGA LONG LETS GOOOO January 22nd 2022, 3:01am |
 |
@InsiderAlerts4U $CMRX: New Insider Filing on CHIMERIX INC's Chief Executive Officer MICHAEL A. SHERMAN: https://t.co/JkabG2yaBz January 21st 2022, 7:01pm |
 |
@Tickeron $CMRX's price moved below its 50-day Moving Average on January 12, 2022. View odds for this and other indicators:… https://t.co/GCi0KRQ2D5 January 21st 2022, 1:01pm |
|
@InsiderAlerts4U $CMRX: New Insider Filing on CHIMERIX INC's Principal Accounting Officer DAVID JAKEMAN: https://t.co/rZ8hbmGI6Y January 21st 2022, 12:01pm |
|
@InsiderAlerts4U $CMRX: New Insider Filing on CHIMERIX INC's Chief Medical Officer ALLEN S. MELEMED: https://t.co/fBY6IMC9pV January 21st 2022, 11:01am |
|
@InsiderAlerts4U $CMRX: New Insider Filing on CHIMERIX INC's Chief Business Officer and CFO MICHAEL T. ANDRIOLE: https://t.co/79eMiIqscK January 21st 2022, 7:01am |
 |
@newsfilterio Chimerix to Present at B. Riley Virtual Oncology Conference $CMRX https://t.co/aGAIG4kat3 January 21st 2022, 4:01am |
|
@Tickeron $CMRX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/OoEmFycKsu January 21st 2022, 1:01am |
 |
@FlashAlert_me $CMRX [15s. delayed] filed SEC form 4: Chief Medical Officer Melemed Allen S.: Transacted Derivative Securities on… https://t.co/E22azWQpFe January 21st 2022, 12:01am |
|
@FlashAlert_me $CMRX [15s. delayed] filed SEC form 4: Principal Accounting Officer Jakeman David: Granted 14,900 of Common Stock… https://t.co/SVnzWzRVzI January 21st 2022, 12:01am |
|
@FlashAlert_me $CMRX [15s. delayed] filed SEC form 4: Chief Business Officer and CFO Andriole Michael T.: Transacted Derivative S… https://t.co/L7Vk4njVpl January 20th 2022, 11:01pm |
|
@FlashAlert_me $CMRX [15s. delayed] filed SEC form 4: Chief Executive Officer Sherman Michael A.: Transacted Derivative Securitie… https://t.co/RaoUp2Noro January 20th 2022, 11:01pm |
 |
@TradeWithAlerts Nice print for $CMRX Size: 112589 Price: 5.58 Amount: $628,246.62 Time: 1600 See more: https://t.co/tHjfNSo0rg Join… https://t.co/3xQtdmvoCi January 20th 2022, 9:01pm |
 |
@ShogunTrade $CMRX Bullish pattern forming. Chart by https://t.co/6vnULU2sSf https://t.co/MUN394cXy7 January 20th 2022, 6:01pm |
 |
@phasefivebot $CMRX Chimerix to Present at B. Riley Virtual Oncology Conference https://t.co/NA90xst0wU January 20th 2022, 1:01pm |
 |
@StockNewsBot2 $CMRX Chimerix to Present at B. Riley Virtual Oncology Conference https://t.co/G8MybY8Czk January 20th 2022, 1:01pm |
 |
@stock_titan $CMRX Chimerix to Present at B. Riley Virtual Oncology Conference https://t.co/3zHSaOWgPk January 20th 2022, 1:01pm |
 |
@bthefirsttoknow First out// $CMRX: Chimerix to Present at B. Riley Virtual Oncology Conference https://t.co/sI182FifZq January 20th 2022, 1:01pm |
 |
@AnotherBio @BertrandBio @bradloncar look at $CMRX. These guys have a multi-million-dollar payback ahead of them, just by kicki… https://t.co/833brmel5P January 20th 2022, 12:01pm |
 |
@NMarmot61 RT @semodough: HCW $CMRX believe these data support potential indications for ONC201 outside H3 K27M-mutant diffuse midline glioma. launch… January 20th 2022, 9:01am |
 |
@Franca_ole It is not a question of if but when $CMRX will break out to the upside! JMHO https://t.co/BP9sAQ8YS6 https://t.co/uyzKWiOAGz January 19th 2022, 10:01pm |
 |
@semodough @buysidebio Mike Sherman no stranger to making a good deal - stay tuned $CMRX January 19th 2022, 5:01pm |
 |
@zbiotech if only $CMRX would have tweaked some western blots in their pub, they'd be en route to a $SAVA mkt cap...ie >3x current January 19th 2022, 4:01pm |
|
@semodough HCW $CMRX believe these data support potential indications for ONC201 outside H3 K27M-mutant diffuse midline glioma… https://t.co/7to6KyqcKn January 19th 2022, 1:01pm |
|
@ShogunTrade $CMRX Awaiting Buy Signal. Chart by https://t.co/6vnULU2sSf https://t.co/JVEoy01YBq January 19th 2022, 12:01pm |
 |
@VatqLu $CMRX Waiting for Buy signal. https://t.co/oivmK9S7CC January 19th 2022, 12:01pm |
 |
@StckPro $CMRX NEW ARTICLE : H.C. Wainwright Thinks Chimerix’s Stock is Going to Recover https://t.co/PoIVY1Jl4o Get all the… https://t.co/COt3oiIxm7 January 19th 2022, 11:01am |
 |
@Briefingcom $CMRX: Chimerix announces publication of ONC201 data from Phase 2 study in neuroendocrine tumors https://t.co/DnAUqI2RTC January 18th 2022, 11:01pm |
 |
@RJ248842 $CMRX data were previously disclosed (as company notes). January 18th 2022, 10:01pm |
 |
@MarcJacksonLA $CMRX Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinica… https://t.co/OY1av4vZ3l January 18th 2022, 10:01pm |
 |
@rozzieryan Should be good for at least -10% $CMRX https://t.co/wStXq97Q8m January 18th 2022, 10:01pm |
 |
@hephaistos_ai RT @GeorgeB14941177: $CMRX Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical #… January 18th 2022, 9:01pm |
 |
@GeorgeB14941177 $CMRX Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinica… https://t.co/Fr3eY0Bnam January 18th 2022, 9:01pm |
 |
@mehabecapital $CMRX @ 5.62 (-6.33%) : Chimerix announces publication of study data for the cancer candidate https://t.co/5qNToAP8yq January 18th 2022, 9:01pm |
 |
@sv_capitalhldg RT @semodough: $CMRX Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer… January 18th 2022, 9:01pm |
 |
@newsinthemarket Chimerix publishes ONC201 study data in Clinical Cancer Research journal $CMRX January 18th 2022, 9:01pm |
 |
@PennyStockNews5 $CMRX ? Sentiments: title -0.2023 | summary -0.3182 Aft-Price: 6 | Bid: 5.66 | Ask: 5.67 Volume: 856,852 https://t.co/P3DBO4nFom January 18th 2022, 9:01pm |
|
@phasefivebot $CMRX Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinica… https://t.co/UdOz6DbXBq January 18th 2022, 9:01pm |
|
@semodough $CMRX Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinica… https://t.co/0ljbiFJgGU January 18th 2022, 9:01pm |
|
@FlashAlert_me $CMRX [15s. delayed]: Issued Press Release on January 18, 16:01:00: Chimerix Announces Publication of Positive ONC2… https://t.co/rxrnis1CSg January 18th 2022, 9:01pm |
 |
@StockTraderHub $CMRX - Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research January 18th 2022, 9:01pm |
|
@StockNewsBot2 $CMRX Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinica… https://t.co/58cPT7dmbZ January 18th 2022, 9:01pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2022. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?